{"title":"上尿路尿路上皮癌患者在接受派姆单抗治疗后的总有效率优于膀胱癌患者。","authors":"Mamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, Takafumi Minami, Wataru Fukuokaya, Keiichiro Mori, Takafumi Yanagisawa, Takuya Tsujino, Ryoichi Maenosono, Masanobu Saruta, Kiyoshi Takahara, Takeshi Hashimoto, Yosuke Hirasawa, Haruhito Azuma, Yoshio Ohno, Ryoichi Shiroki, Kazutoshi Fujita","doi":"10.21037/tau-2025-254","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The treatment strategy for urothelial carcinoma has advanced with the development of enfortumab vedotin (EV); however, a comparative analysis of its therapeutic efficacy between upper urinary tract urothelial carcinoma (UTUC) and bladder cancer (BCa) has yet to be established. We aimed to compare the effects of EV after pembrolizumab treatment between the patients with UTUC and BCa.</p><p><strong>Methods: </strong>We included the patients with advanced UC patients who received EV after pembrolizumab in this retrospective study. We investigated the impact of various clinical variables including age, primary site of disease (UTUC <i>vs.</i> BCa), Liver metastasis, lung metastasis, prior number of regimens before EV treatment, and ECOG PS, which influenced on prognosis and efficacy of EV treatment.</p><p><strong>Results: </strong>A total of 63 male and 23 female patients were included in our study. The number of UTUC and BCa patients were 33 and 53, respectively. The UTUC cohort had a significantly older patient population and a greater incidence of lung metastases compared to the BCa group. The prognosis of UTUC patients were not significantly different from BCa patients. However, UTUC was determined as significant factor to predict better overall response rate than BCa in multiple logistic regression analysis.</p><p><strong>Conclusions: </strong>UTUC patients showed significantly better response to EV treatment than BCa patients.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"14 8","pages":"2279-2288"},"PeriodicalIF":1.7000,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433179/pdf/","citationCount":"0","resultStr":"{\"title\":\"Upper urinary tract urothelial carcinoma patients show better overall response rate than bladder cancer patients during enfortumab vedotin treatment following pembrolizumab.\",\"authors\":\"Mamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, Takafumi Minami, Wataru Fukuokaya, Keiichiro Mori, Takafumi Yanagisawa, Takuya Tsujino, Ryoichi Maenosono, Masanobu Saruta, Kiyoshi Takahara, Takeshi Hashimoto, Yosuke Hirasawa, Haruhito Azuma, Yoshio Ohno, Ryoichi Shiroki, Kazutoshi Fujita\",\"doi\":\"10.21037/tau-2025-254\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The treatment strategy for urothelial carcinoma has advanced with the development of enfortumab vedotin (EV); however, a comparative analysis of its therapeutic efficacy between upper urinary tract urothelial carcinoma (UTUC) and bladder cancer (BCa) has yet to be established. We aimed to compare the effects of EV after pembrolizumab treatment between the patients with UTUC and BCa.</p><p><strong>Methods: </strong>We included the patients with advanced UC patients who received EV after pembrolizumab in this retrospective study. We investigated the impact of various clinical variables including age, primary site of disease (UTUC <i>vs.</i> BCa), Liver metastasis, lung metastasis, prior number of regimens before EV treatment, and ECOG PS, which influenced on prognosis and efficacy of EV treatment.</p><p><strong>Results: </strong>A total of 63 male and 23 female patients were included in our study. The number of UTUC and BCa patients were 33 and 53, respectively. The UTUC cohort had a significantly older patient population and a greater incidence of lung metastases compared to the BCa group. The prognosis of UTUC patients were not significantly different from BCa patients. However, UTUC was determined as significant factor to predict better overall response rate than BCa in multiple logistic regression analysis.</p><p><strong>Conclusions: </strong>UTUC patients showed significantly better response to EV treatment than BCa patients.</p>\",\"PeriodicalId\":23270,\"journal\":{\"name\":\"Translational andrology and urology\",\"volume\":\"14 8\",\"pages\":\"2279-2288\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-08-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433179/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational andrology and urology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21037/tau-2025-254\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"ANDROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational andrology and urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tau-2025-254","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/22 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ANDROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：尿路上皮癌的治疗策略随着艾弗妥单抗（EV）的发展而不断进步；然而，其治疗上尿路尿路上皮癌（UTUC）与膀胱癌（BCa）的疗效对比分析尚未建立。我们的目的是比较pembrolizumab治疗后UTUC和BCa患者的EV效果。方法：我们在这项回顾性研究中纳入了派姆单抗后接受EV治疗的晚期UC患者。我们研究了年龄、原发部位（UTUC vs. BCa）、肝转移、肺转移、治疗前治疗方案数量、ECOG PS等临床变量对EV治疗预后和疗效的影响。结果：本研究共纳入63例男性患者和23例女性患者。UTUC和BCa患者分别为33例和53例。与BCa组相比，UTUC组患者年龄较大，肺转移发生率更高。UTUC患者的预后与BCa患者无显著差异。然而，在多元logistic回归分析中，UTUC被确定为预测总有效率优于BCa的显著因素。结论：UTUC患者对EV治疗的反应明显优于BCa患者。
Upper urinary tract urothelial carcinoma patients show better overall response rate than bladder cancer patients during enfortumab vedotin treatment following pembrolizumab.
Background: The treatment strategy for urothelial carcinoma has advanced with the development of enfortumab vedotin (EV); however, a comparative analysis of its therapeutic efficacy between upper urinary tract urothelial carcinoma (UTUC) and bladder cancer (BCa) has yet to be established. We aimed to compare the effects of EV after pembrolizumab treatment between the patients with UTUC and BCa.
Methods: We included the patients with advanced UC patients who received EV after pembrolizumab in this retrospective study. We investigated the impact of various clinical variables including age, primary site of disease (UTUC vs. BCa), Liver metastasis, lung metastasis, prior number of regimens before EV treatment, and ECOG PS, which influenced on prognosis and efficacy of EV treatment.
Results: A total of 63 male and 23 female patients were included in our study. The number of UTUC and BCa patients were 33 and 53, respectively. The UTUC cohort had a significantly older patient population and a greater incidence of lung metastases compared to the BCa group. The prognosis of UTUC patients were not significantly different from BCa patients. However, UTUC was determined as significant factor to predict better overall response rate than BCa in multiple logistic regression analysis.
Conclusions: UTUC patients showed significantly better response to EV treatment than BCa patients.
期刊介绍：
ranslational Andrology and Urology (Print ISSN 2223-4683; Online ISSN 2223-4691; Transl Androl Urol; TAU) is an open access, peer-reviewed, bi-monthly journal (quarterly published from Mar.2012 - Dec. 2014). The main focus of the journal is to describe new findings in the field of translational research of Andrology and Urology, provides current and practical information on basic research and clinical investigations of Andrology and Urology. Specific areas of interest include, but not limited to, molecular study, pathology, biology and technical advances related to andrology and urology. Topics cover range from evaluation, prevention, diagnosis, therapy, prognosis, rehabilitation and future challenges to urology and andrology. Contributions pertinent to urology and andrology are also included from related fields such as public health, basic sciences, education, sociology, and nursing.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
